Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro. 2017

Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
Institute of Respiratory and Occupational Diseases, Collaborative Innovation Center for Cancer, Shanxi Datong University, Datong, Shanxi 037009, P.R. China.

ABCB1 (P-glycoprotein, ABCB1/MDR1) is one of the major members of the ABC transporters linked to MDR in cancer cells. In this study, we observed that pristimerin, a natural triterpenoid, potently decreased P-gp in a dose-dependent manner in both drug-resistant KBv200 and stable transfected HEK293/ABCB1 cell lines. Moreover, pristimerin also inhibited cell proliferation and induced apoptosis in both cell lines. Intriguingly, reverse transcription-PCR, real-time PCR and protein turn-over assay revealed that the decrease of P-gp was independent of mRNA level but primarily owing to its protein stability. Furthermore, immunofluorescence study with anti-P-gp antibody showed that pristimerin disturbed the subcellular distribution of P-gp with decreased location in the plasma membrane. Taken together, these data suggest that subcellular distribution of P-gp and subsequent downregulation by pristimerin contribute to overcoming ABCB1-mediated chemotherapeutic drug resistance. Our findings suggested inducing the decrease of P-gp membrane protein could be a new promising alternative therapeutic strategy in ABCB1-mediated MDR.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014315 Triterpenes A class of terpenes (the general formula C30H48) formed by the condensation of six isoprene units, equivalent to three terpene units. Triterpene,Triterpenoid,Triterpenoids
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D053978 Pentacyclic Triterpenes Five-ring derivatives of dammarane having a chair-chair-chair-boat configuration. They include the lupanes, oleananes, amyrins, GLYCYRRHIZIC ACID, and soyasaponins. Adianane Derivatives,Adiananes,Baccharane Triterpenes,Fernane Derivatives,Fernanes,Gammacerane Derivatives,Gammaceranes,Hopane Derivatives,Hopanes,Hopenoid Derivatives,Pentacyclic Triterpenoids,Triterpenes, Pentacyclic,Triterpenes, Baccharane
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D018435 ATP Binding Cassette Transporter, Subfamily B A subfamily of transmembrane proteins from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS that are closely related in sequence to ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1. When overexpressed, they function as ATP-dependent efflux pumps able to extrude lipophilic drugs (especially ANTINEOPLASTIC AGENTS) from cells, causing multidrug resistance (DRUG RESISTANCE, MULTIPLE). Although ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B share functional similarities to MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS they are two distinct subclasses of ATP-BINDING CASSETTE TRANSPORTERS, and have little sequence homology. Multidrug Resistance Proteins,P-Glycoproteins,ATP Binding Cassette Transporter, Sub-Family B,ATP-Binding Cassette, Sub-Family B Proteins,ATP Binding Cassette Transporter, Sub Family B,ATP Binding Cassette, Sub Family B Proteins,P Glycoproteins

Related Publications

Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
February 2019, Drug metabolism and disposition: the biological fate of chemicals,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
January 2020, Frontiers in pharmacology,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
December 2004, Leukemia,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
April 2011, Cancer research,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
August 2014, Future oncology (London, England),
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
April 2016, Oncotarget,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
May 2023, Neoplasia (New York, N.Y.),
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
December 2018, Biochemical pharmacology,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
March 2020, Journal of ginseng research,
Yan-Yan Yan, and Fang Wang, and Xiao-Qin Zhao, and Xiao-Kun Wang, and Yi-Fan Chen, and Hong Liu, and Yong Xie, and Li-Wu Fu
December 2002, Molecular cancer therapeutics,
Copied contents to your clipboard!